IDELALISIB | IDELALISIB | ATC L01XX47
ANTINEOPLASTIC PHOSPHOINOSITIDE 3-KINASE INHIBITOR TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA AND RELAPSED SMALL LYMPHOCYTIC LYMPHOMA (SLL) INDUCE APOPTOSIS | ORAL | Tmax 1.5 HOUR VD 23 LITER PPB 84 PERCENT Cl 14.9 LITER / HOUR HT 8.2 HOUR SOLUBILITY PH-DEPENDENT AQUEOUS SOLUBILITY 0.1 MILLIGRAM / MILLILITER (PH 5-7) | PHOSPHOINOSITIDE 3-KINASE DELTA PDB 4XE0 (IDELALISIB BOUND TO THE P110 SUBUNIT OF PI3K DELTA) LIGAND CODE = 40L (link to the list of PDB complexes) Download experimental 3D coordinates of 40L with added hydrogens | PI3-KINASE P110-DELTA SUBUNIT INHIBITOR CHEMBL3130 PI3-KINASE P110-DELTA SUBUNIT O00329 PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM HOMO SAPIENS ENZYME | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |